This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
Experimental Hematology & Oncology Open Access 28 March 2019
-
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation
Journal for ImmunoTherapy of Cancer Open Access 21 February 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jenq RR, van den Brink MRM . Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10: 213–221.
Armand P . Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125: 3393–3400.
Davids MS, Kim HT, Costello CL, Avigan D, Chen Y-B, Armand P et al. A multicenter phase I study of CTLA-4 blockade with Ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Blood 2014; 124 abstract 3964.
Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 2013; 122: 3062–3073.
Cecchini M, Sznol M, Seropian S . Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. J Immunother Cancer 2015; 3: 10.
Townsend W, Linch D . Hodgkin's lymphoma in adults. Lancet 2012; 380: 836–847.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183–2189.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853–1862.
Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN . Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone Marrow Transplant 2014; 49: 599–606.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 Blockade with Nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.
Moskowitz CH, Ribrag V, Michot J-M, Martinelli G, Zinzani PL, Gutierrez M et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood 2014; 124 abstract 290.
Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009; 113: 2265–2274.
Stelljes M, Hermann S, Albring J, Köhler G, Löffler M, Franzius C et al. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood 2008; 111: 2909–2918.
Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934–1941.
Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH . Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015; 373: 288–290.
Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Angenendt, L., Schliemann, C., Lutz, M. et al. Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 51, 443–445 (2016). https://doi.org/10.1038/bmt.2015.266
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.266
This article is cited by
-
Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2023)
-
Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review
Bone Marrow Transplantation (2021)
-
Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
Experimental Hematology & Oncology (2019)
-
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
Journal of Cancer Research and Clinical Oncology (2019)
-
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation
Journal for ImmunoTherapy of Cancer (2017)